145 related articles for article (PubMed ID: 12393684)
1. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease.
Giuliani N; Colla S; Sala R; Moroni M; Lazzaretti M; La Monica S; Bonomini S; Hojden M; Sammarelli G; Barillè S; Bataille R; Rizzoli V
Blood; 2002 Dec; 100(13):4615-21. PubMed ID: 12393684
[TBL] [Abstract][Full Text] [Related]
2. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma.
Qiang YW; Chen Y; Stephens O; Brown N; Chen B; Epstein J; Barlogie B; Shaughnessy JD
Blood; 2008 Jul; 112(1):196-207. PubMed ID: 18305214
[TBL] [Abstract][Full Text] [Related]
3. B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease.
Kawai T; Matsuyama T; Hosokawa Y; Makihira S; Seki M; Karimbux NY; Goncalves RB; Valverde P; Dibart S; Li YP; Miranda LA; Ernst CW; Izumi Y; Taubman MA
Am J Pathol; 2006 Sep; 169(3):987-98. PubMed ID: 16936272
[TBL] [Abstract][Full Text] [Related]
4. It never rains but it pours: potential role of butyrophilins in inhibiting anti-tumor immune responses.
Cubillos-Ruiz JR; Conejo-Garcia JR
Cell Cycle; 2011 Feb; 10(3):368-9. PubMed ID: 21270530
[No Abstract] [Full Text] [Related]
5. Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma.
Dhodapkar KM; Barbuto S; Matthews P; Kukreja A; Mazumder A; Vesole D; Jagannath S; Dhodapkar MV
Blood; 2008 Oct; 112(7):2878-85. PubMed ID: 18669891
[TBL] [Abstract][Full Text] [Related]
6. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index.
Terpos E; Szydlo R; Apperley JF; Hatjiharissi E; Politou M; Meletis J; Viniou N; Yataganas X; Goldman JM; Rahemtulla A
Blood; 2003 Aug; 102(3):1064-9. PubMed ID: 12689925
[TBL] [Abstract][Full Text] [Related]
7. Dissecting molecular mechanisms of immune microenvironment dysfunction in multiple myeloma and precursor conditions.
Moscvin M; Evans B; Bianchi G
J Cancer Metastasis Treat; 2023; 9():. PubMed ID: 38213954
[TBL] [Abstract][Full Text] [Related]
8. Novel Developments in the Treatment of Multiple Myeloma-Associated Bone Disease.
Johansen M; Levring MB; Stokbro K; Diaz-delCastillo M; Khan AA; Wickstroem LA; Gundesen MT; Kristensen IB; Nyvold CG; Andersen MØ; Andersen TL; Abildgaard N; Lund T
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067289
[TBL] [Abstract][Full Text] [Related]
9. BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions.
Sun F; Cheng Y; Chen JR; Wanchai V; Mery DE; Xu H; Gai D; Al Hadidi S; Schinke C; Thanendrarajan S; Zangari M; van Rhee F; Tricot G; Shaughnessy JD; Zhan F
J Clin Invest; 2024 Jan; 134(1):. PubMed ID: 37883186
[TBL] [Abstract][Full Text] [Related]
10. The Role of XBP1 in bone metabolism.
Lv W; Zheng Y; Jiao J; Fu Y; Xu T; Zhang L; Zhang Z; Ma N
Front Endocrinol (Lausanne); 2023; 14():1217579. PubMed ID: 37795354
[TBL] [Abstract][Full Text] [Related]
11. The Ins and Outs of Endosteal Niche Disruption in the Bone Marrow: Relevance for Myeloma Oncogenesis.
Capp JP; Bataille R
Biology (Basel); 2023 Jul; 12(7):. PubMed ID: 37508420
[TBL] [Abstract][Full Text] [Related]
12. Immune microenvironment: novel perspectives on bone regeneration disorder in osteoradionecrosis of the jaws.
Chen H; Liu Z; Yue K; Ding J; He Y
Cell Tissue Res; 2023 May; 392(2):413-430. PubMed ID: 36737519
[TBL] [Abstract][Full Text] [Related]
13. Bone Metastasis in Bladder Cancer.
Yi L; Ai K; Li X; Li Z; Li Y
J Pers Med; 2022 Dec; 13(1):. PubMed ID: 36675715
[TBL] [Abstract][Full Text] [Related]
14. Normalization of the Immunological Microenvironment and Sustained Minimal Residual Disease Negativity: Do We Need Both for Long-Term Control of Multiple Myeloma?
Bertuglia G; Cani L; Larocca A; Gay F; D'Agostino M
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555520
[TBL] [Abstract][Full Text] [Related]
15. Bone Metastasis of Breast Cancer: Molecular Mechanisms and Therapeutic Strategies.
Pang L; Gan C; Xu J; Jia Y; Chai J; Huang R; Li A; Ge H; Yu S; Cheng H
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497209
[TBL] [Abstract][Full Text] [Related]
16. Pathophysiology and therapeutic advances in myeloma bone disease.
Zhang F; Zhuang J
Chronic Dis Transl Med; 2022 Dec; 8(4):264-270. PubMed ID: 36420171
[TBL] [Abstract][Full Text] [Related]
17. CK1α/RUNX2 Axis in the Bone Marrow Microenvironment: A Novel Therapeutic Target in Multiple Myeloma.
Fregnani A; Saggin L; Gianesin K; Quotti Tubi L; Carraro M; Barilà G; Scapinello G; Bonetto G; Pesavento M; Berno T; Branca A; Gurrieri C; Zambello R; Semenzato G; Trentin L; Manni S; Piazza F
Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077711
[TBL] [Abstract][Full Text] [Related]
18. Quantitative systems pharmacology modeling sheds light into the dose response relationship of a trispecific T cell engager in multiple myeloma.
Abrams RE; Pierre K; El-Murr N; Seung E; Wu L; Luna E; Mehta R; Li J; Larabi K; Ahmed M; Pelekanou V; Yang ZY; van de Velde H; Stamatelos SK
Sci Rep; 2022 Jun; 12(1):10976. PubMed ID: 35768621
[TBL] [Abstract][Full Text] [Related]
19. Secondary Osteoporosis and Metabolic Bone Diseases.
Sobh MM; Abdalbary M; Elnagar S; Nagy E; Elshabrawy N; Abdelsalam M; Asadipooya K; El-Husseini A
J Clin Med; 2022 Apr; 11(9):. PubMed ID: 35566509
[TBL] [Abstract][Full Text] [Related]
20. The Role of the Immune Microenvironment in Bone Regeneration.
Yang N; Liu Y
Int J Med Sci; 2021; 18(16):3697-3707. PubMed ID: 34790042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
